MétaCan
Menu
← Back to cohort
Record W4390193045 · doi:10.1002/alz.079734

Selective targeting and protection against toxic amyloid‐beta oligomers by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer’s disease

2023· article· en· W4390193045 on OpenAlexaff
Neil R. Cashman, Ebrima Gibbs, Judith M. Silverman, Beibei Zhao, Juliane Coutts, Xubiao Peng, Steven S. Plotkin, Johanne Kaplan

Bibliographic record

VenueAlzheimer s & Dementia · 2023
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsAmorfix (Canada)University of British Columbia
Fundersnot available
KeywordsIn vivoMonoclonal antibodyAntibodyEpitopeChemistryPotencyThioflavinIn vitroAmyloid (mycology)Amyloid betaPharmacologyBiochemistryPeptideMolecular biologyAlzheimer's diseaseBiologyImmunologyMedicinePathologyDisease

Abstract

fetched live from OpenAlex

Abstract Background A large body of evidence indicates that the most pathogenic species of amyloid‐beta (Aß) in Alzheimer’s disease (AD) consists of soluble toxic oligomers (AßO) as opposed to insoluble fibrils and monomers. Clinical results to date indicate that non‐selective antibodies that bind Aß monomers, oligomers and plaque fail to provide a therapeutic benefit. Partially selective antibodies that bind AßO and plaque have shown improved success but are associated with dose‐limiting adverse events (amyloid‐related imaging abnormalities; ARIA). These findings suggest that antibodies capable of selectively neutralizing toxic AßO may achieve improved efficacy and safety. Monoclonal antibody PMN310 was raised against a conformational epitope predicted by computational modeling to be exposed on toxic AßO but not monomers or fibrils. A summary of the selectivity and protective activity of PMN310 against toxic AßO in vitro and in vivo is presented. Method The binding selectivity of PMN310 was characterized and compared to that of other Aß‐directed antibodies by surface plasmon resonance (SPR) and immunohistochemistry (IHC). Its ability to neutralize the propagation and toxicity of AßO was assessed in vitro in a thioflavin‐T propagation assay and in cultures of primary rodent neurons, respectively. In vivo protective activity was tested in wild‐type mice injected intracerebroventricularly (ICV) with AßO and in the APP/L transgenic mouse model of AD. Result In SPR analysis, PMN310 showed selective binding to AßO over monomers and, compared to otherAß‐directed antibodies, was minimally impacted by monomer competition in binding to toxic oligomers from AD brain extract. In addition, PMN310 did not bind to Aß plaque or vascular deposits as determined by IHC suggesting a potentially reduced risk of ARIA compared to other Aß‐directed antibodies. In vitro, PMN310 inhibited AßO propagation and neuronal toxicity. In vivo, PMN310 prevented AßO‐induced loss of memory formation after ICV injection. Systemic administration to APP/L transgenic mice preserved memory and learning in the water maze task. Conclusion The antibody PMN310 was shown to selectively bind toxic AßO and protect against their pathogenic activity in vitro. In two rodent models of AD, PMN310 protected memory function, suggesting that PMN310 may offer a new therapeutic option for the treatment or prevention of AD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.000
Threshold uncertainty score0.002

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.039
GPT teacher head0.316
Teacher spread0.277 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→